



## **Blueprint Medicines to Present at the 33<sup>rd</sup> Annual J.P. Morgan Healthcare Conference**

**CAMBRIDGE, Mass. January 8, 2015** – Blueprint Medicines, a leader in discovering and developing kinase drugs to treat patients with genetically defined diseases, today announced that Jeffrey Albers, Chief Executive Officer, will present a company overview at the 33<sup>rd</sup> Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 9:30 a.m. PST at the Westin St. Francis Hotel in San Francisco, CA.

### **About Blueprint Medicines**

Blueprint Medicines makes kinase drugs to treat patients with genetically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer. Blueprint Medicines is privately held and raised \$115 million in financing since its 2011 inception. For more information, please visit [www.BlueprintMedicines.com](http://www.BlueprintMedicines.com).

###

### **Contact:**

Investor Relations:

Beth DelGiacco

Stern Investor Relations, Inc.

212-362-1200

[beth@sternir.com](mailto:beth@sternir.com)

Media Relations:

David Polk

Chandler Chicco Companies

310-309-1029

[dpolk@chandlerchicco.com](mailto:dpolk@chandlerchicco.com)